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A B S T R A C T
Objectives: Menopause involves hypoestrogenism, which is associated with numerous detrimental effects, in-
cluding on respiratory health. Hormone replacement therapy (HRT) is often used to improve symptoms of
menopause. The effects of HRT on lung function decline, hence lung ageing, have not yet been investigated
despite the recognized effects of HRT on other health outcomes.
Study design: The population-based multi-centre European Community Respiratory Health Survey provided
complete data for 275 oral HRT users at two time points, who were matched with 383 nonusers and analysed
with a two-level linear mixed effects regression model.
Main outcome measures: We studied whether HRT use was associated with the annual decline in forced vital
capacity (FVC) and forced expiratory volume in one second (FEV1).
Results: Lung function of women using oral HRT for more than five years declined less rapidly than that of
nonusers. The adjusted difference in FVC decline was 5.6 mL/y (95%CI: 1.8 to 9.3, p = 0.01) for women who
had taken HRT for six to ten years and 8.9 mL/y (3.5 to 14.2, p = 0.003) for those who had taken it for more
than ten years. The adjusted difference in FEV1 decline was 4.4 mL/y (0.9 to 8.0, p = 0.02) with treatment from
six to ten years and 5.3 mL/y (0.4 to 10.2, p = 0.048) with treatment for over ten years.
Conclusions: In this longitudinal population-based study, the decline in lung function was less rapid in women
who used HRT, following a dose-response pattern, and consistent when adjusting for potential confounding
factors. This may signify that female sex hormones are of importance for lung ageing.
1. Introduction
Health after menopause becomes increasingly important as life spans
lengthen. For many women, menopause is a midlife event [1], which might
increase the risk of various diseases due to postmenopausal hypoestro-
genism. The role of endocrine factors in respiratory health is increasingly
acknowledged and studies have identified menopause as a predictor of new-
onset asthma [2]. Menopause is further associated with lower lung function
[3,4] as well as an acceleration of the naturally occurring lung function
decline [5]. Postmenopausal hypoestrogenism is commonly systemically
counteracted by oral hormone replacement therapy (HRT). Other options
include dermal patches and vaginal preparations. It seems that HRT is a
double-edged sword; it may hold benefits for some women while it may
harm others. Originally developed to treat symptoms of the menopausal
transition, it is now established that HRT largely prevents the long-term
frailties of osteoporosis [6] and it has been associated with a reduced risk of
lung and colorectal cancer [7,8]. Hormone replacement therapy is however
also associated with an increased risk of ovarian and endometrial cancer
[9,10] as well as asthma [11,12] Preparations containing progestins are
amongst others associated with an increased risk of breast cancer [13,14].
The existing literature on the relationship between HRT and lung function
consists of two cross-sectional studies and three small clinical trials, gen-
erally portraying HRT as being beneficial for the lungs [15–19]. The aim of
the present study was to investigate whether oral HRT reduces the naturally
Fig. 1. Flow chart of the study population.
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occurring lung function decline over a 20-year period in matched subsets of
a large, population-based cohort.
2. Methods
2.1. Study population
The European Community Respiratory Health Survey (ECRHS) is a
population-based international and prospective cohort study (www.ecrhs.
org). The present analysis includes 658 women (275 HRT ever users, 383
nonusers) from 22 study centres in nine countries (see online supplement).
We used data from baseline in 1991–1994 and follow-up in 2010–2012
with a median observation time of 20.0 years (range: 17.9–22.4). The ex-
aminations consisted of an interviewer-led questionnaire on respiratory
health and lifestyle factors as well as spirometry. At follow-up, women also
answered a questionnaire on reproductive health. The ECRHS provided
serum samples at follow-up for a subgroup of the study population
(N=169). These samples were analysed for 17β-estradiol at the Core
Facility for Metabolomics, University of Bergen (Norway) by liquid chro-
matography – tandem mass spectrometry. We performed the regression
analysis on 275 HRT ever users, containing 125 past users and 150 current
users. Eighty-four current users reported HRT constituents: estradiol com-
bined with a progestin (N=50), tibolone (N=18), estradiol only
(N=16). The study did not provide details of the HRT constituents of past
users. Ethical approval was obtained from the appropriate ethics commit-
tees of each study centre at each wave and all participants provided in-
formed written consent.
2.2. Statistical analysis and inclusion criteria
Our exposure measure was the number of years women used oral
HRT. This information was extracted from the answers to the following
two questions at follow-up: 1) “How long in total did you take the fol-
lowing types of hormonal treatments for the menopause (oral prepara-
tions)?” and 2) “For each year of age between 40 and now, please tick the
years when you took the following types of hormonal treatments for the
menopause (oral preparations)”. Women using dermal patches or vaginal
preparations were excluded from the analysis. The outcome, lung
function, was recorded at baseline and follow-up, according to stan-
dardized spirometry procedures [20]. The specific outcome variables
were the difference of FVC, respectively FEV1 between baseline and
follow-up, divided by the individual follow-up time, which can be in-
terpreted as the annual lung function decline [mL/y]. A positive re-
gression coefficient thus indicates a less rapid decline of lung function,
respectively a smaller change in lung function between study waves in
the corresponding group. Interviewers, who also gathered the in-
formation about age, pack-years of cigarettes and age at completed full-
time education, measured the covariates weight and height. As age at
menopause, we used the age at bilateral oophorectomy or the age at the
last menstruation. All included participants reached menopause, as they
reported amenorrhea for more than 12 months at follow-up. The spe-
cific questions were: 1)“Do you have regular periods?” Options: “Yes”,
“No, they have never been regular”, “No, they have been irregular for a few
months”, “No, my periods have stopped” and 2) “When was your last
period?”. We identified 327 menopausal women who reported use of
oral HRT (range: 1–19 years). We performed a complete case analysis
and excluded women with missing data on pack-years, age at meno-
pause, weight at follow-up, and age at completed full-time education.
The remaining 275 HRT users were matched with suitable nonusers
(N = 383), who reported never using oral HRT. We analysed four si-
milar-sized subgroups of women taking HRT according to duration of
use: 1–2 years, 3–5 years, 6–10 years and more than 10 years (Fig. 1).
HRT users and nonusers were matched non-parametrically using the
Mahalanobis distance measure for matching according to a 1:n
matching scheme [21]. Since the analyses of the four subgroups were
separate from each other, nonusers were matched multiple times as
long as their distance measure was within the convex hull. Matching
enables a more robust and less sensitive subsequent regression analysis
by selecting the best control matches for each HRT user [22]. We
matched HRT users and nonusers by age, age at menopause, height
(baseline), weight (baseline), age at completed full-time education. We
evaluated the balance between HRT users and nonusers in the full data
set, and in the matched data, using quantile-quantile plots of each
matching variable (see online data supplement). To compare the
Table 1
Anthropometrics, pack-years and pulmonary function of the matched study participants using HRT for 1–2 years and 3–5 years, mean (Standard deviation) unless
indicated otherwise.
Nonusers HRT (1-2y) p1 Nonusers HRT (3-5y) p1
n 355 102 248 70
Age (baseline) [y] 35.94 (4.32) 36.26 (5.71) 0.53 38.48 (2.92) 39.87 (4.30) < 0.001
Age (follow-up) [y] 55.88 (4.24) 56.32 (5.63) 0.39 58.47 (2.84) 59.88 (4.08) < 0.001
Age (menopause) [y] 49.35 (3.15) 49.00 (4.44) 0.37 50.18 (2.94) 49.94 (4.41) 0.59
Age (compl. education) [y] 20.89 (3.01) 21.20 (5.44) 0.46 20.17 (2.91) 21.71 (5.81) < 0.001
Weight at baseline [kg] 62.38 (7.24) 63.48 (9.57) 0.21 62.52 (7.70) 62.53 (11.55) 0.99
Δ Weight [kg] 9.37 (8.39) 9.69 (10.03) 0.75 8.07 (7.79) 7.21 (7.62) 0.41
Height (baseline) [m] 1.63 (0.05) 1.64 (0.06) 0.26 1.64 (0.04) 1.63 (0.06) 0.42
Δ Height [m] −0.01 (0.02) −0.01 (0.02) 0.04 −0.01 (0.02) −0.01 (0.02) 0.64
Pack-years [median (IQR2)] 0.00 [0.00, 8.00] 0.00 [0.00, 11.88] 0.41 0.00 [0.00, 8.00] 0.00 [0.00, 6.44] 0.84
Δ Pack-years [median (IQR2)] 0.00 [0.00, 1.81] 0.00 [0.00, 3.18] 0.34 0.00 [0.00, 0.00] 0.00 [0.00, 1.38] 0.45
FVC3 (baseline) [mL] 3.88 (0.50) 3.87 (0.51) 0.89 3.88 (0.48) 3.75 (0.56) 0.05
Δ FVC3 [mL/y] −0.03 (0.01) −0.03 (0.02) 0.07 −0.03 (0.02) −0.03 (0.02) 0.23
FEV14 (baseline) [mL] 3.20 (0.43) 3.18 (0.47) 0.68 3.18 (0.42) 3.10 (0.44) 0.17
Δ FEV14 [mL/y] −0.03 (0.01) −0.04 (0.02) 0.18 −0.04 (0.01) −0.03 (0.02) 0.55
Predicted FVC3 (baseline) [%] 102.91 (11.42) 102.05 (9.92) 0.49 102.91 (11.25) 100.94 (12.86) 0.21
Predicted FEV14 (baseline) [%] 102.42 (12.29) 101.16 (11.64) 0.36 102.58 (12.62) 101.96 (12.98) 0.72
Predicted FVC3 (follow-up) [%] 101.64 (12.98) 99.79 (12.50) 0.20 101.56 (13.32) 101.40 (15.66) 0.94
Predicted FEV14 (follow-up) [%] 97.25 (14.16) 95.09 (15.21) 0.18 96.93 (14.57) 97.17 (15.39) 0.91
Respiratory symptoms5 N (%) 39 (11.0) 8 (7.8) 0.46 33 (13.3) 10 (14.3) 0.99
1 T-test for continuous variables, X2-test for categorical variables, Kruskal-Wallis test for nonnormal variables (pack-years).
2 Interquartile range.
3 Forced vital capacity.
4 Forced expiratory volume in one second.
5 Asthma attack during the last 12 months, breathless while wheezing at any time in the last 12 months, woken up with a feeling of tightness in your chest at any
time in the last 12 months, or woken by an attack of shortness of breath at any time in the last 12 months.
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groups, we used two-level linear mixed effects regression models (level
1 unit: subject; level 2 unit: centre) with a random intercept term at
level 2. The models were further adjusted for study centre, the differ-
ence in weight, height and pack-years between baseline and follow-up
(extant exposure during the time period over which lung function
change was measured), as well as the type of spirometer, as spirometers
differed between centres and study waves (see online data supplement).
We further stratified the analysis into current and past users. To in-
vestigate a potential trend, we performed a Mann-Kendall trend test
without continuity correction. All analyses were performed using
RStudio (Version 1.0.136, The R Foundation for Statistical Computing).
3. Results
Anthropometrics, pack-years and pulmonary function of the mat-
ched subgroups are presented in Tables 1 and 2. With the 1:n matching
scheme (with multiple use of nonuser observations), each of the sui-
table 383 nonusers were matched on average 2.5 times leading to a
total of 960 observations of nonusers being matched to the 275 HRT
users (included total observations: 1235). Detailed information on the
balance before and after matching (quantile-quantile plots for matching
variables) can be found in the online data supplement. We evaluated
serum 17β-estradiol in a subset of the population (N = 169). In the
exposure group, consisting of past and current users of oral HRT, we
calculated a median concentration of 73.3 pmol/L (Inter quartile range
(IQR): 12.1–169.3) for current users and 10.0 pmol/L (IQR: 5.6–18.6)
for past users. Nonusers had a median estradiol concentration of
10.5 pmol/L (IQR: 5.4–16.5).
The adjusted regression analysis showed that the use of oral HRT for
more than 5 years was associated with a reduced decline of FVC and
FEV1 compared with non-use. Associations were statistically significant
for treatment durations greater than five years (Table 3 and Fig. 2).
Overall, FVC and FEV1 showed a very similar pattern as well as a dose-
response like relationship (ptrend = 0.04). The stratified analysis into
current and past users showed that the association was more pro-
nounced amongst current HRT users (online data supplement).
4. Discussion
This study on matched subgroups of a population-based interna-
tional cohort found that lung function decline was significantly reduced
in women taking oral HRT for more than five years, compared to
women who never used oral HRT. For the individual women the effect
sizes might not be of practical importance, but the results indicate that
oral HRT compensates roughly one third of the postmenopausal accel-
eration of lung function decline [5] if it is used for six to ten years,
respectively, and half if it is used for more than ten years. The results
seem plausible, as elevated estrogens are likely to protect lung function
[23,24]. In animal studies, increased systemic estrogen levels have been
shown to improve metabolic and inflammatory profiles [24,25] and a
comprehensive review concluded that estradiol overall has an anti-in-
flammatory effect on the lungs [23]. Estrogens also protect from os-
teoporosis, which might preserve the integrity of thoracic vertebrae and
maintain an optimal expansion of the thoracic cage during inspiration
[26].
The main reason to start an HRT regiment is distress caused by
symptoms of the menopausal transition, which lasts on average five
Table 2
Anthropometrics, pack-years and pulmonary function of the matched study participants using HRT for 6–10 years and more than 10 years, mean (Standard deviation)
unless indicated otherwise.
Nonusers HRT (6-10y) p1 Nonusers HRT (> 10y) p1
n 286 67 71 36
Age (baseline) [y] 38.15 (3.89) 40.37 (4.88) < 0.001 41.32 (2.21) 42.15 (3.75) 0.15
Age (follow-up) [y] 58.15 (3.85) 60.48 (4.78) < 0.001 61.40 (2.14) 62.00 (3.59) 0.29
Age (menopause) [y] 49.19 (3.27) 49.15 (4.43) 0.94 47.29 (4.24) 45.25 (6.72) 0.06
Age (compl. education) [y] 19.55 (3.03) 19.87 (5.17) 0.51 19.42 (2.41) 20.53 (4.53) 0.10
Weight at baseline [kg] 61.91 (6.61) 62.54 (10.62) 0.54 61.62 (6.33) 60.94 (10.69) 0.68
Δ Weight [kg] 8.23 (8.22) 7.77 (7.91) 0.68 7.81 (7.65) 10.23 (8.30) 0.14
Height (baseline) [m] 1.64 (0.05) 1.65 (0.07) 0.17 1.63 (0.04) 1.63 (0.06) 0.57
Δ Height [m] −0.01 (0.02) −0.01 (0.01) 0.37 −0.01 (0.02) −0.02 (0.02) 0.63
Pack-years [median (IQR2)] 0.00 [0.00, 9.00] 0.00 [0.00, 9.50] 0.81 0.00 [0.00, 2.45] 0.00 [0.00, 11.29] 0.20
Δ Pack-years [median (IQR2)] 0.00 [0.00, 0.00] 0.00 [0.00, 2.80] 0.28 0.00 [0.00, 0.00] 0.00 [0.00, 6.07] 0.04
FVC3 (baseline) [mL] 3.91 (0.50) 3.76 (0.59) 0.04 3.73 (0.50) 3.56 (0.49) 0.11
Δ FVC3 [mL/y] −0.03 (0.01) −0.02 (0.02) 0.07 −0.03 (0.01) −0.02 (0.01) 0.01
FEV14 (baseline) [mL] 3.21 (0.43) 3.05 (0.50) 0.01 3.06 (0.39) 2.95 (0.48) 0.22
Δ FEV14 [mL/y] −0.04 (0.01) −0.03 (0.02) 0.07 −0.04 (0.01) −0.03 (0.01) 0.07
Predicted FVC3 (baseline) [%] 102.70 (11.14) 98.43 (11.20) 0.01 101.26 (11.20) 97.02 (13.51) 0.09
Predicted FEV14 (baseline) [%] 102.59 (12.45) 97.69 (12.74) < 0.001 101.93 (11.87) 98.65 (15.65) 0.23
Predicted FVC3 (follow-up) [%] 101.86 (13.42) 100.91 (12.75) 0.60 99.89 (14.47) 100.25 (15.32) 0.91
Predicted FEV14 (follow-up) [%] 97.15 (14.49) 94.98 (13.92) 0.27 95.88 (15.28) 96.14 (16.55) 0.94
Respiratory symptoms5 N (%) 38 (13.3) 12 (17.9) 0.43 7 (9.9) 6 (16.7) 0.48
1 T-test for continuous variables, X2-test for categorical variables, Kruskal-Wallis test for nonnormal variables (pack-years).
2 Interquartile range.
3 Forced vital capacity.
4 Forced expiratory volume in one second.
5 Asthma attack during the last 12 months, breathless while wheezing at any time in the last 12 months, woken up with a feeling of tightness in your chest at any
time in the last 12 months, or woken by an attack of shortness of breath at any time in the last 12 months.
Table 3
Differences in the change of forced vital capacity (FVC) and forced expiratory
volume in one second (FEV1) of hormone replacement therapy (HRT) users
compared with nonusers (A positive regression coefficient indicates a less rapid
decline of lung function).
FVC FEV1
HRT treatment β [mL/y] (95% CI)1 p β [mL/y] (95% CI)1 p
None Reference Reference
1–2 years (n = 86) −2.2 (−5.2 to 0.8) 0.16 −2.1 (−4.7 to 0.5) 0.12
3–5 years (n = 72) 2.2 (−1.7 to 6.0) 0.28 2.0 (−1.7 to 5.6) 0.30
6–10 years (n = 70) 5.6 (1.8–9.3) 0.01 4.4 (0.9–8.0) 0.02
> 10 years (n = 39) 8.9 (3.5–14.2) 0.003 5.3 (0.4–10.2) 0.048
1 Coefficients and 95% confidence intervals of the linear mixed effects model
adjusted for age, age at menopause, weight (baseline), weight change, height,
height change, pack-years since baseline, age at completed full-time education,
type of spirometer and study centre.
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years [27]. During this phase, concentrations of estradiol may differ
substantially and even be elevated [28]. The process of the transition
possibly overshadows the early effect of HRT on lung function decline.
This may contribute to the non-significant results for using HRT for less
than five years. It might further be possible that women, who chose to
use HRT have more severe menopausal symptoms, thus the beneficial
effect of HRT may have been observed mainly in this group. However,
this does not necessarily limit the potential benefit to women with se-
vere menopausal symptoms.
This study focuses on oral HRT as it represents a systemic as well as
the most frequent treatment. A potential issue with HRT treatment over
a long time is compliance. Women may have stopped the treatment
periodically to evaluate the continuity of transitional symptoms. This
may introduce a minor bias, and the results would underestimate the
true effect. Further when the Women’s Health Initiative study was
published in 2002, many women worldwide stopped taking HRT. As
our study is retrospective and covering this time point, it is likely that
this applies to some women in our study population and this might
attenuate associations.
To our knowledge, this is the first longitudinal study investigating
HRT and the decline of lung function. Of two previous cross-sectional
studies, Carlson et al reported that current HRT users older than 65
years, had higher FEV1 compared to nonusers [15], whereas Jarvis et al
observed this association only in overweight, past HRT-users [16]. Due
to the different study designs, comparability is limited between studies.
Cevrioglu et al, in one of two clinical trials on volunteers, lasting three
months, found an increased lung function in 23 women treated with a
continuous estrogen and progestin preparation compared to 25 women
who did not take HRT [17]. Pata et al, in the second trial on volunteers
(N = 75) reported an increased lung function after treatment with Ti-
bolone, combined estrogens and progestins as well as estrogen only
preparations, but this study did not have a control group [18]. A
drawback of both studies on volunteers might be that they are under-
powered and subject to selection bias. Stipic et al in the third trial re-
ported increased FEV1 in 30 HRT users who underwent surgery because
of genital prolapse compared to nonusers after six months of treatment
[19]. Overall, our results are in agreement with the previous work in
the field. Our analysis adds external validity and the use of objective
hormone measurements, the long follow-up time and the high response
rates are strengths of our study [29]. Weaknesses of the study are the
unknown history of HRT types, which did not allow stratification ac-
cording to the active ingredients (estrogen with and without progestin)
and the non-randomized use, as users could have more menopausal
symptoms or be more health conscious [30]. The latter is accounted for
by matching HRT users with the most similar nonusers. There was no
statistically significant difference in the age at completed full-time
education within the groups yielding statistically significant results (our
proxy for socio-economic status) and it seems unlikely that the observed
associations could be explained by unobserved differences.
5. Conclusions
Oral hormone replacement therapy for six years or more is asso-
ciated with a reduced decline of lung function. Even though the effect
size might be irrelevant for the individual women, this supports the idea
that the accelerated loss of lung function during menopause may be
explained by hypoestrogenism. Our findings are relevant for the ne-
cessary further research on lung ageing.
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